Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EHA 2019 /
Safety and efficacy of escalating doses of Hu5F9-G4 with rituximab in patients with R/R DLBCL and indolent lymphoma

13th - 16th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 20.06.19
Views: 641
Rating:

Dr Mark Roschewski - National Cancer Institute, Bethesda, USA

Dr Mark Roschewski speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting on the phase IB/2 results of a study evaluating the safety and efficacy of escalating doses of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab in patients with R/R DLBCL and indolent lymphoma.

He explains that the study enrolled patients who were ineligible for CAR T therapy as they would be considered as having very limited treatment options.

Dr Roschewski reports that the escalating of doses means that anaemia is less of a problem and it causes the patient's haemoglobin to rise over time.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation